SURGIBOT

UNDER DEVELOPMENT · PHASE 2 AUTONOMY TARGET: 2035

DESIGNED AROUND
THE SURGEON.
A PATH TOWARD AUTONOMY.

We are developing a surgeon-controlled robotic platform first, with a second phase targeting defined autonomous capabilities by 2035. Neither phase is currently a clinically available product.

SEE HOW IT LEARNS

BUILT TO PERCEIVE, REASON AND ACT

SurgiBot is conceived as a multi-arm surgical robot: articulated instrument arms, surgeon-grade vision and a compact operating-room platform. The development programme aims to learn from governed surgical data and progress from surgeon-controlled assistance toward bounded autonomous action.

SEE

Fuse 4K, ICG and procedural signals into a live understanding of the surgical field.

UNDERSTAND

Recognise anatomy, instruments, workflow stage and safety boundaries.

PLAN

Select a validated sequence of movements for a defined surgical task.

ACT

Execute precise motion with continuous monitoring and human override.

SURGIBOT / SRS PRODUCT SPECIFICATIONS

WHAT WE ARE BUILDING.

A four-arm, surgeon-controlled surgical robot with force feedback, stereo vision and on-device intelligence. The SRS defines the engineering targets for the system under development.

UNDER DEVELOPMENT · ENGINEERING TARGETS
These are planned specifications, not measured or clinically validated performance. Safety standards are design requirements, not certifications. Autonomy and remote operation require further validation and applicable regulatory authorisation.

Four-arm control

Three instrument arms and one camera arm, with wristed instruments and provision for a fifth-arm bracket.

Touch feedback

Fibre Bragg grating (FBG) sensing in the instrument shaft, targeting force resolution below 0.1 N at the tip.

4K stereo vision

Stereo 3D imaging with integrated near-infrared / ICG fluorescence and a target of 60–120 frames per second.

Real-time tissue AI

On-device tissue segmentation, targeting at least 90% mean intersection-over-union (mIoU) with a 30 fps overlay.

Reusable instruments

A 7-DOF wristed instrument range in 8 mm and 5 mm formats, targeting at least 50 sterilisation cycles.

Supervised autonomy

Phase 2 targets defined autonomous capabilities by 2035, with surgeon oversight and an independent safety processor; subject to validation and approvals.

System & motion

Configuration: Rigid multi-port, four-arm teleoperated soft-tissue surgical robot
System components: Surgeon console, patient cart and vision tower
Design approach: Vertically integrated, India-built platform
Arm arrangement: 3 instrument arms + 1 camera arm; provision for a fifth-arm bracket
Joint architecture: Backdrivable direct-drive + harmonic reduction
Arm degrees of freedom: 7-DOF wristed per arm + 1, as specified in the SRS
Arm reach: ≥ 850 mm trocar-to-pivot
Position repeatability: < 0.3 mm; ISO 9283 measurement basis

Force feedback & imaging

Force sensing: FBG sensing in the instrument shaft
Force resolution: < 0.1 N at the instrument tip
Haptic response: < 10 ms end-to-end latency; 1 kHz rendering
Imaging: 4K stereo 3D; 8K-ready design target
Video performance: 60–120 fps; < 70 ms latency
Fluorescence: Integrated near-infrared / ICG imaging
Endoscopes: 8 mm, 0° / 30°; 5 mm on the roadmap

Instruments & surgeon console

Instrument range: 7-DOF wristed instruments; 8 mm and 5 mm
Reuse life: ≥ 50 sterilisation cycles
Instrument recognition: RFID auto-dock
Sterilisation design: Pre-vacuum autoclave, 132–134°C; process validation required
Console display: 4K OLED stereo; 55 pixels per degree
Console controls: Open console, eye tracking and force-feedback master controls; optional head-mounted display

AI, connectivity & safety

Edge computing: NVIDIA Orin-class inference
Tissue segmentation: ≥ 90% mIoU target with a 30 fps overlay; validation dataset and clinical performance to be established
Autonomy roadmap: Phase 1: surgeon-controlled platform. Phase 2: defined autonomous capabilities targeted for 2035, subject to validation and applicable approvals.
Connectivity: Over-the-air updates and fleet learning; telesurgery latency target < 200 ms
Safety architecture: SIL-2 design target, dual watchdogs and independent safety CPU; emergency-stop response < 200 ms
Electrical & security design targets: IEC 60601-1 Class I, Type CF; EMC Class B; IEC 62443 security requirements
Power & backup: 100–240 VAC, 50/60 Hz; 10-minute UPS on the patient cart
Integrated equipment: UnivLabs OEM electrosurgical unit and insufflator
Operating environment: 10–30°C; 10–85% relative humidity, non-condensing

Physical dimensions & installation targets

Target dimensions — height × base width and depth shown separately
Component	Height	Width × depth	Base footprint	Weight
Surgeon console	130–195 cm	85 × 100 cm	≈ 0.85 m²	≤ 250 kg
Patient cart	150–230 cm	90 × 125 cm	≈ 1.13 m²	≤ 550 kg
Vision tower	180–225 cm	80 × 90 cm	≈ 0.72 m²	≤ 350 kg

Patient-cart deployed length: 170–225 cm. Ground clearance: ≥ 32 mm. Combined system weight: approximately 1,150 kg. Doorway clearance target: ≥ 200 cm high × 100 cm wide. Elevator capacity target: ≥ 750 kg for component transport; site-specific handling requirements must be confirmed.

Source: SRS Robotics product specification and dimensions workbook. Final specifications remain subject to engineering verification.

HOW SURGIBOT LEARNS FROM SURGERY

The planned learning pathway starts with authorised surgical recordings. Governed data preparation, model research, simulation and controlled studies would follow. Any robotic capability must be separately validated before clinical use.

80MSURGERIES — DATA VISION

SurgiBot's development programme targets learning from a governed corpus representing up to 80 million surgeries, subject to lawful access, consent, data rights, quality controls and applicable regulatory requirements.

ONE LOOPSURGERY → INTELLIGENCE → ACTION

Each validated deployment can return governed performance data to improve the system.

TWO PHASES. A CLEAR DEVELOPMENT PATH.

Phase 1 is a surgeon-controlled robotic platform, currently under development. Phase 2 targets defined autonomous capabilities by 2035—not unrestricted autonomous surgery.

PHASE 1 · UNDER DEVELOPMENT

SURGEON-CONTROLLED PLATFORM

Robotic instruments, stereo vision, force feedback and surgeon override. Availability depends on verification, clinical evidence and applicable approvals.

PHASE 2 · DEVELOPMENT TARGET 2035

DEFINED AUTONOMOUS CAPABILITIES

Supervised, bounded tasks developed through simulation and controlled validation. A target date is not a product launch or clinical-use commitment.

Candidate research areas — not approved indications

DIAGNOSTIC LAPAROSCOPY

Systematic visual survey, landmark recognition and documentation.

TISSUE RETRACTION AND CAMERA CONTROL

Stable visualisation and coordinated instrument positioning.

CHOLECYSTECTOMY ASSISTANCE

Exposure, anatomy recognition and selected standardised steps.

APPENDECTOMY STEPS AND TURP

Identification, controlled dissection, camera control and selected repeatable steps under specialist supervision.

The Phase 2 target of 2035 is a development ambition, not a clinical promise. Scope and timing will depend on engineering validation, clinical evidence, ethics review, regulatory authorisation, patient selection and human oversight.

HUMAN CONTROL AT EVERY STAGE

✓ Surgeon override✓ Defined operating boundaries✓ Continuous safety monitoring✓ Traceable decisions✓ Progressive clinical validation✓ Regulatory pathway

SurgiBot will advance through supervised task autonomy before any consideration of broader procedural autonomy.

DISCUSS SURGIBOT

DESIGNED AROUNDTHE SURGEON.A PATH TOWARD AUTONOMY.